Clinical Cancer Research
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma
2023
-
Evaluating the impact of COVID-19 on medical oncology workforce and cancer care in Canada: A serial survey study.
2020
-
Abstract A24: Identifying the genomic and clinical features of AKT1/PIK3CA mutant metastatic prostate cancer using circulating tumor DNA
2020
-
Abstract A26: Defining VALUE: Routine liquid biopsy in NSCLC diagnosis—a Canadian trial in progress
2020
-
Defining VALUE: Routine liquid biopsy in NSCLC diagnosis-a Canadian trial in progress
2020
-
Identifying the genomic and clinical features of AKT1/PIK3CA mutant metastatic prostate cancer using circulating tumor DNA
2020
-
Abstract B28: Targeted inhibition of EGFR and glutaminase induces metabolic crisis in EGFR-mutant lung cancer
2018
-
Abstract A53: Combining oncolytic virotherapy with immunotherapy for ovarian cancer treatment.
2016
-
Abstract B06: Chemotherapeutic agents attenuate subsequent CXCL12-induced migration of colon cancer cells by selecting for CXCR4-negative cells and increasing peptidase CD26
2015
-
Multistate Analysis of Skeletal Events in Patients with Bone Metastases
2006
-
Managing patients on endocrine therapy: Focus on quality-of-life issues
2006
-
A phase 2 study of GTI-2040 plus docetaxel and prednisone as 1st line treatment in hormone-refractory prostate cancer (HRPC).
2005
-
A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally recurrent endometrial cancer - NCICCTG IND 160.
2005
-
Cetuximab improves locoregional control and survival of locoregionally advanced head and neck cancer: Independent review of mature data with a median follow-up of 45 months.
2005
-
Correlation between erlotinib concentrations and severity of skin rash.
2005
-
Down-regulation of CXCR4 expression on colorectal carcinoma cells by prostaglandins is partially mediated by PPAR gamma.
2005
-
Evaluation of adverse events experienced by older patients participating in studies of molecularly targeted agents alone or in combination.
2005
-
HGS-ETR1, a fully human agonistic monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) in patients with advanced solid cancer: Results of a phase 1 trial.
2005
-
Pharmacodynamic evaluations of paired tumor biopsies in advanced neuroendocrine carcinomas (NECs) treated with the mTOR inhibitor temsirolimus.
2005
-
Pharmacodynamic studies of erlotinib in tumor and skin tissue samples of patients (Pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).
2005
-
Phase I study of daily oral AZD 2171, an inhibitor of the vascular endothelial growth factor receptor (VEGFR), in combination with carboplatin/paclitaxel in patients with advanced non-small cell lung cancer (NSCLC): A study of the NCICCTG.
2005
-
Phase II study of sorafenib (BAY 43-9006) in combination with gemcitabine in recurrent epithelial ovarian cancer: A study of the PMH phase II consortium.
2005
-
A phase I/Il Study of erlotinib (Tarceva) in combination with cisplatin in patients with recurrent or metastatic squamous cell cancer of the head and neck (HNSCC).
2003
-
A phase I/Il Study of erlotinib (Tarceva) in combination with cisplatin in patients with recurrent or metastatic squamous cell cancer of the head and neck (HNSCC).
2003
-
A phase II trial of the proteosome inhibitor PS-341 (Bortezomib; Velcade)in patients with metastatic colorectal cancer.
2003
-
Phase II study of erlotinib (Tarceva, OSI774) in women with recurrent or metastatic endometrial cancer - NCICIND 148.
2003
-
Phase II study of topotecan (T) in combination with the novel kinase inhibitor ucUCN-01 in patients with advanced cancer.
2003
-
Initial results of part 2 of a phase I/II pharmacokinetics (PK), pharmacodynamic (PD), and biological activity study of ZD1839 (Iressa (TM)): NCICCTG IND.122.
2001
-
Mutants with restricted subcellular localization reveal different mechanisms and potencies for Bcl-2 and Bcl-XL mediated inhibition of doxorubicin induced apoptosis.
2001
-
Neovastat (Æ-941) in addition to combined modality therapy for locally-advanced unresectable non-small cell lung cancer (NSCLC):: An NCI-sponsored multicenter phase III study.
2001
-
Phase I study to determine the safety and pharmacokinetics of BAY 43-9006 in patients with advanced refractory solid tumors.
2001
-
Against erbB-2 over-expressing breast cancer cells or chronic myelogenous leukemia cells with bcr-abl translocation thorough destabilization of erbB-2 or bcr-abl oncoproteins.
2000
-
Phase II study of c-raf kinase antisense oligonucleotide ISIS 5132 in patients (pts) with recurrent ovarian cancer - NCICIND.116.
2000
-
Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
2000
-
BAY 12-9566, a selective, non-peptidic biphenyl inhibitor of matrix metalloproteases (MMPs): summary of phase I clinical and pharmacokinetic (PK) results.
1999
-
Phase I study of NX211 given as an intravenous infusion on days 1, 2 & 3 every 3 weeks in patients (pts) with solid tumors - an NCIC Clinical Trials Group study.
1999
-
Æ-941, an inhibitor of angiogenesis:: Rationale for a phase III study on Æ-941 in combination with induction chemotherapy/radiotherapy in patients with non small cell lung cancer (NSCLC).
1999
-
Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration Resistant Prostate Cancer..
of1-of11.
2024
-
Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial.
30:1509-1517.
2024
-
Intratumoral Delivery of Chimeric Antigen Receptor T Cells Targeting CD133 Effectively Treats Brain Metastases.
30:554-563.
2024
-
Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma.
30:63-73.
2024
-
HDACi-dependent Microenvironmental Normalization Overcomes Tumor Burden–induced T-cell Exhaustion.
29:4289-4305.
2023
-
Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA.
29:92-99.
2023
-
Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade.
28:5180-5189.
2022
-
Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial.
28:738-747.
2022
-
Predictive Significance of an Optimized Panel for Basal-like Breast Cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 Phase III Clinical Trials.
27:6570-6579.
2021
-
Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study.
27:3884-3895.
2021
-
MRI and 18FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial.
27:179-188.
2021
-
Abstract PO-016: Evaluating the impact of COVID-19 on medical oncology workforce and cancer care in Canada: A serial survey study.
26:po-016-po-016.
2020
-
Abstract PO-068: Efforts to define biochemical and pharmacologic pathways potentially beneficial to both cancer and COVID-19 patients.
26:po-068-po-068.
2020
-
PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma.
26:2956-2971.
2020
-
Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86).
26:2477-2486.
2020
-
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.
26:1009-1016.
2020
-
Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer.
26:1114-1125.
2020
-
Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221.
25:6052-6060.
2019
-
TAp73 Modifies Metabolism and Positively Regulates Growth of Cancer Stem–Like Cells in a Redox-Sensitive Manner.
25:2001-2017.
2019
-
Combining Vascular Normalization with an Oncolytic Virus Enhances Immunotherapy in a Preclinical Model of Advanced-Stage Ovarian Cancer.
25:1624-1638.
2019
-
A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer.
23:935-945.
2017
-
Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.
22:2897-2907.
2016
-
Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor–Initiating Cells.
21:5324-5337.
2015
-
The Urgent Need for Clinical Research Reform to Permit Faster, Less Expensive Access to New Therapies for Lethal Diseases.
21:4561-4568.
2015
-
Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype.
21:3750-3758.
2015
-
Molecular Pathways: Leveraging the BCL-2 Interactome to Kill Cancer Cells—Mitochondrial Outer Membrane Permeabilization and Beyond.
21:2671-2676.
2015
-
Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate.
21:1621-1627.
2015
-
Molecular Pathways: Epigenetic Modulation of Wnt–Glycogen Synthase Kinase-3 Signaling to Target Human Cancer Stem Cells.
20:5372-5378.
2014
-
A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epstein–Barr Virus (EBV) Target Antigens: A Phase I Trial in UK Patients with EBV-Positive Cancer.
20:5009-5022.
2014
-
Use of the Proton Pump Inhibitor Pantoprazole to Modify the Distribution and Activity of Doxorubicin: A Potential Strategy to Improve the Therapy of Solid Tumors.
19:6766-6776.
2013
-
Quantitative Ultrasound Evaluation of Tumor Cell Death Response in Locally Advanced Breast Cancer Patients Receiving Chemotherapy.
19:2163-2174.
2013
-
Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial.
18:2402-2412.
2012
-
Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c.
17:5765-5773.
2011
-
Phase I Study of Decitabine in Combination with Vorinostat in Patients with Advanced Solid Tumors and Non-Hodgkin's Lymphomas.
17:1582-1590.
2011
-
Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non–Small Cell Lung Cancer Patients.
16:2881-2889.
2010
-
Vascular Endothelial Growth Factor Concentration as a Predictive Marker: Ready for Primetime?.
16:1341-1341.
2010
-
Vascular Endothelial Growth Factor Polymorphisms and Esophageal Cancer Prognosis.
15:4680-4685.
2009
-
Phase I study of intravenous decitabine in combination with oral vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas (NHL).
27:3528-3528.
2009
-
p53 Arg72Pro and MDM2 T309G Polymorphisms, Histology, and Esophageal Cancer Prognosis.
15:3103-3109.
2009
-
Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment.
15:2920-2926.
2009
-
Quantitative Ultrasound Characterization of Responses to Radiotherapy in Cancer Mouse Models.
15:2067-2075.
2009
-
Phase II Trial of OGX-011 in Combination with Docetaxel in Metastatic Breast Cancer.
15:708-713.
2009
-
Imaging Intratumoral Convection: Pressure-Dependent Enhancement in Chemotherapeutic Delivery to Solid Tumors.
15:247-255.
2009
-
Preferential Killing of Breast Tumor Initiating Cells by N,N-Diethyl-2-[4-(Phenylmethyl)Phenoxy]Ethanamine/Tesmilifene.
15:119-130.
2009
-
Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab.
14:7554-7563.
2008
-
Oncostatin M Induces Bone Loss and Sensitizes Rat Osteosarcoma to the Antitumor Effect of MidostaurinIn vivo.
14:5400-5409.
2008
-
A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies.
14:3450-3455.
2008
-
Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study.
14:2763-2767.
2008
-
Improving the Quality of Abstract Reporting for Phase I Cancer Trials.
14:1782-1787.
2008
-
A Phase I Study of OGX-011, a 2′-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer.
14:833-839.
2008
-
Is There a Human Homologue to the Murine Proteolysis-Inducing Factor?.
13:4984-4992.
2007
-
Phase I Targeted Combination Trial of Sorafenib and Erlotinib in Patients with Advanced Solid Tumors.
13:4849-4857.
2007
-
Body Composition as an Independent Determinant of 5-Fluorouracil–Based Chemotherapy Toxicity.
13:3264-3268.
2007
-
An Optimized Clinical Regimen for the Oncolytic Virus PV701.
13:977-985.
2007
-
Establishment in Severe Combined Immunodeficiency Mice of Subrenal Capsule Xenografts and Transplantable Tumor Lines from a Variety of Primary Human Lung Cancers: Potential Models for Studying Tumor Progression–Related Changes.
12:4043-4054.
2006
-
Markers of Bone Metabolism and Survival in Men with Hormone-Refractory Metastatic Prostate Cancer.
12:3361-3367.
2006
-
Evaluation of Adverse Events Experienced by Older Patients Participating in Studies of Molecularly Targeted Agents Alone or in Combination.
12:2141-2149.
2006
-
Managing Patients on Endocrine Therapy: Focus on Quality-of-Life Issues.
12:1056s-1060s.
2006
-
Objective Responses in Patients with Malignant Melanoma or Renal Cell Cancer in Early Clinical Studies Do Not Predict Regulatory Approval.
11:5928-5934.
2005
-
A Phase II Trial with Pharmacodynamic Endpoints of the Proteasome Inhibitor Bortezomib in Patients with Metastatic Colorectal Cancer.
11:5526-5533.
2005
-
Flavopiridol Sensitivity of Cancer Cells Isolated from Ascites and Pleural Fluids.
11:3523-3529.
2005
-
Phase I Trial of the Matrix Metalloproteinase Inhibitor Marimastat Combined with Carboplatin and Paclitaxel in Patients with Advanced Non–Small Cell Lung Cancer.
11:3417-3424.
2005
-
Results of a Multicenter Randomized Phase II Trial of Thalidomide and Prednisone Maintenance Therapy for Multiple Myeloma after Autologous Stem Cell Transplant.
10:8170-8176.
2004
-
A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients..
9:2457-2464.
2003
-
A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases..
7:478-485.
2001
-
Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer..
6:2349-2355.
2000
-
Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways..
6:1917-1921.
2000
-
Immunoenzymatically determined pepsinogen C concentration in breast tumor cytosols: an independent favorable prognostic factor in node-positive patients..
5:1778-1785.
1999
-
Analysis of FUS-CHOP fusion transcripts in different types of soft tissue liposarcoma and their diagnostic implications..
4:1779-1784.
1998
-
Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study..
4:1489-1497.
1998
-
Telomerase: A potential marker of bladder transitional cell carcinoma in bladder washes.
4:535-538.
1998
-
Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer.
2:1255-1261.
1996
has subject area
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)